The simplicity of therapy, ease of dose adjustment and blood glucose monitoring, the low relative risk of hypoglycaemia, and limited weight gain, has increased the confidence of non‐endocrinologists to make prescribing decisions and today basal insulin treatment is often initiated by general practitioners and nurses.10, 11. This evidence concerns the gene INS and Hypoglycemia.